BioWorld

July 9, 2007

View Archived Issues

Silence Signs AstraZeneca To $400M Respiratory Drug Deal

In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld Today) Read More

Reata Raises $25M In Series E To Fund Development Programs

Read More

Translational Development: The Al Mann Way

Read More

Genzyme's Tolevamer Fails In First Phase III CDAD Trial

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More